Sionna Therapeutics, Inc. (NASDAQ:SION) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Sionna Therapeutics, Inc. (NASDAQ:SION) have been assigned an average rating of “Moderate Buy” from the nine brokerages that are currently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $45.4286.

Several research firms have recently weighed in on SION. Raymond James Financial reaffirmed a “strong-buy” rating and set a $53.00 price objective on shares of Sionna Therapeutics in a report on Monday, January 5th. Lifesci Capital started coverage on Sionna Therapeutics in a research report on Tuesday, December 23rd. They issued an “outperform” rating and a $60.00 price objective for the company. Wall Street Zen upgraded Sionna Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, December 13th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sionna Therapeutics in a report on Monday, December 29th. Finally, Royal Bank Of Canada reiterated an “underperform” rating and set a $24.00 price target on shares of Sionna Therapeutics in a research report on Monday, December 1st.

Insider Activity at Sionna Therapeutics

In other Sionna Therapeutics news, CEO Michael Cloonan sold 99,800 shares of the company’s stock in a transaction on Tuesday, October 21st. The stock was sold at an average price of $36.26, for a total transaction of $3,618,748.00. Following the transaction, the chief executive officer owned 547,343 shares of the company’s stock, valued at approximately $19,846,657.18. This represents a 15.42% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ra Capital Management, L.P. sold 311,000 shares of Sionna Therapeutics stock in a transaction on Friday, October 24th. The shares were sold at an average price of $39.50, for a total value of $12,284,500.00. Following the completion of the sale, the director directly owned 219,867 shares of the company’s stock, valued at $8,684,746.50. This trade represents a 58.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 1,501,826 shares of company stock valued at $56,263,103 in the last three months. 3.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Sionna Therapeutics

Large investors have recently made changes to their positions in the company. SG Americas Securities LLC acquired a new stake in Sionna Therapeutics in the fourth quarter worth about $440,000. Millennium Management LLC boosted its stake in shares of Sionna Therapeutics by 1,425.5% in the 3rd quarter. Millennium Management LLC now owns 214,085 shares of the company’s stock valued at $6,296,000 after purchasing an additional 200,051 shares during the last quarter. Jain Global LLC acquired a new stake in shares of Sionna Therapeutics during the 3rd quarter worth approximately $250,000. Bank of America Corp DE raised its stake in shares of Sionna Therapeutics by 8.8% during the third quarter. Bank of America Corp DE now owns 6,541 shares of the company’s stock worth $192,000 after buying an additional 529 shares during the last quarter. Finally, Longaeva Partners L.P. acquired a new position in Sionna Therapeutics in the third quarter valued at approximately $1,807,000.

Sionna Therapeutics Price Performance

Sionna Therapeutics stock opened at $39.25 on Tuesday. The firm has a market capitalization of $1.75 billion and a P/E ratio of -8.06. The stock has a fifty day moving average price of $40.43 and a two-hundred day moving average price of $30.02. Sionna Therapeutics has a 52-week low of $7.26 and a 52-week high of $45.00.

Sionna Therapeutics (NASDAQ:SION) last posted its earnings results on Wednesday, November 5th. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.06.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.